- Report
- November 2021
- 844 Pages
Global
From €4778EUR$5,000USD£4,066GBP
- Report
- December 2023
- 279 Pages
Global
From €3526EUR$3,690USD£3,000GBP
- Report
- October 2022
- 229 Pages
Global
From €3412EUR$3,570USD£2,903GBP
- Report
- September 2021
- 198 Pages
Global
From €3547EUR$3,712USD£3,018GBP
- Report
- May 2023
- 160 Pages
Global
From €5733EUR$5,999USD£4,878GBP
- Report
- April 2023
- 160 Pages
Global
From €5733EUR$5,999USD£4,878GBP
- Book
- October 2023
Global
- Book
- September 2023
Global
Serotonin is a neurotransmitter found in the central nervous system (CNS) that plays a role in regulating mood, appetite, sleep, and other bodily functions. It is a key target for drugs used to treat depression, anxiety, and other mental health disorders. Serotonin-based drugs are typically selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). These drugs work by blocking the reuptake of serotonin, allowing it to remain active in the brain for longer periods of time.
The serotonin market is a subset of the larger CNS drug market, which is estimated to be worth billions of dollars. It is a highly competitive market, with many large pharmaceutical companies vying for market share. Companies in the serotonin market include Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, and Bristol-Myers Squibb. Show Less Read more